Autophagy is involved in oral rAAV/Aβ vaccine-induced Aβ clearance in APP/PS1 transgenic mice

Neuroscience Bulletin

Volumn 31, Issue 4, 2015, Pages 491-504

  Wang, He Cheng ^a   Zhang, Tao ^a   Kuerban, Bolati ^a   Jin, Ying Lan ^a   Le, Weidong ^b   Hara, Hideo ^c   Fan, Dong Sheng ^d   Wang, Yan Jiang ^e   Tabira, Takeshi ^f   Chui, De Hua ^a,d  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

^c SAGA UNIVERSITY   (Japan)

^d PEKING UNIVERSITY THIRD HOSPITAL   (China)

^e THIRD MILITARY MEDICAL UNIVERSITY   (China)

^f JUNTENDO UNIVERSITY   (Japan)

Author keywords

Akt mTOR pathway; Alzheimer s disease; autophagy; A clearance; oral vaccination

Indexed keywords

ADENOVIRUS VECTOR; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BETA ACTIN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN AGGREGATE; PROTEIN KINASE B; PROTEIN P62; AMYLOID BETA-PROTEIN (1-43); AMYLOID PRECURSOR PROTEIN; MTOR PROTEIN, HUMAN; PEPTIDE FRAGMENT; PRESENILIN 1; PSEN1 PROTEIN, HUMAN; RECOMBINANT PROTEIN; TARGET OF RAPAMYCIN KINASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; BRAIN CORTEX; CELL LYSATE; COMPLEMENT SYSTEM; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; GENOME; HEK293 CELL LINE; HIPPOCAMPUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; UPREGULATION; VACCINATION; ANIMAL; BRAIN; DEPENDOPARVOVIRUS; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; ORAL DRUG ADMINISTRATION; TRANSGENIC MOUSE;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; AUTOPHAGY; BRAIN; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; HEK293 CELLS; HUMANS; MALE; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PRESENILIN-1; PROTO-ONCOGENE PROTEINS C-AKT; RECOMBINANT PROTEINS; TOR SERINE-THREONINE KINASES;

EID: 84938848101     PISSN: 16737067     EISSN: 19958218     Source Type: Journal    
DOI: 10.1007/s12264-015-1546-4     Document Type: Article

References (76)

1. Citron M. Alzheimer’s disease: strategies for disease modification. Nat Rev Drug Discov 2010, 9: 387–398.
2. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002, 297: 353–356.
3. Krstic D, Knuesel I. Deciphering the mechanism underlying late-onset alzheimer disease. Nat Rev Neurol 2013, 9: 25–34.
4. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science 2010, 330: 1774.
5. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400: 173–177.
6. Wisniewski T, Goni F. Immunotherapy for Alzheimer’s disease. Biochem Pharmacol 2014, 88: 499–507.
7. Wisniewski T. Active immunotherapy for Alzheimer’s disease. Lancet Neurol 2012, 11: 571–572.
8. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mildto- moderate Alzheimer’s disease. N Engl J Med 2014, 370: 322–333.
9. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-tomoderate Alzheimer’s disease. N Engl J Med 2014, 370: 311–321.
10. Hara H, Monsonego A, Yuasa K, Adachi K, Xiao X, Takeda S, et al. Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer’s disease. J Alzheimers Dis 2004, 6: 483–488.
11. Mouri A, Noda Y, Hara H, Mizoguchi H, Tabira T, Nabeshima T. Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. FASEB J 2007, 21: 2135–2148.
12. Ghavami S, Shojaei S, Yeganeh B, Ande SR, Jangamreddy JR, Mehrpour M, et al. Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog Neurobiol 2014, 112: 24–49.
13. Wong Y C, Holzbaur EL. Autophagosome dynamics in neurodegeneration at a glance. J Cell Sci 2015, 128: 1259–1267.
14. Chui DH, Tanahashi H, Ozawa K, Ikeda S, Checler F, Ueda O, et al. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nat Med 1999, 5: 560–564.
15. Steele J W, Gandy S. Latrepirdine (Dimebon(R)), a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse model. Autophagy 2013, 9: 617–618.
16. Shibuya Y, Chang CC, Huang LH, Bryleva EY, Chang TY. Inhibiting ACAT1/SOAT1 in microglia stimulates autophagymediated lysosomal proteolysis and increases Abeta1-42 clearance. J Neurosci 2014, 34: 14484–14501.
17. Kuballa P, Nolte WM, Castoreno AB, Xavier RJ. Autophagy and the immune system. Annu Rev Immunol 2012, 30: 611–646.
18. Saiga H, Nieuwenhuizen N, Gengenbacher M, Koehler A, Schuerer S, Moura- Alves P, et al. The recombinant BCG DeltaureC::hly vaccine targets the AIM2 inflammasome to induce autophagy and inflammation. J Infect Dis 2014.
19. Jackson WT. Viruses and the autophagy pathway. Virology 2015, 479–480: 450–456.
20. Dong X, Tian W, Wang G, Dong Z, Shen W, Zheng G, et al. Establishment of an AAV reverse infection-based array. PLoS One 2010, 5: e13479.
21. Tong Y, Yang H, Tian X, Wang H, Zhou T, Zhang S, et al. High manganese, a risk for Alzheimer’s disease: high manganese induces amyloid-beta related cognitive impairment. J Alzheimers Dis 2014, 42: 865–878.
22. Carrera I, Etcheverria I, Fernandez-Novoa L, Lombardi VR, Lakshmana MK, Cacabelos R, et al. A comparative evaluation of a novel vaccine in APP/PS1 mouse models of Alzheimer’s disease. Biomed Res Int 2015, 2015: 807146.
23. Webster SJ, Bachstetter AD, Nelson PT, Schmitt FA, Van Eldik LJ. Using mice to model Alzheimer’s dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front Genet 2014, 5: 88.
24. Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A 2010, 107: 7036–7041.
25. Li W, Yu J, Liu Y, Huang X, Abumaria N, Zhu Y, et al. Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer’s disease mouse model. Mol Brain 2014, 7: 65.
26. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med 1996, 2: 864–870.
27. Xian X, Liu T, Yu J, Wang Y, Miao Y, Zhang J, et al. Presynaptic defects underlying impaired learning and memory function in lipoprotein lipase-deficient mice. J Neurosci 2009, 29: 4681–4685.
28. Yu Y, Zhou L, Sun M, Zhou T, Zhong K, Wang H, et al. Xylocoside G reduces amyloid-beta induced neurotoxicity by inhibiting NF-kappaB signaling pathway in neuronal cells. J Alzheimers Dis 2012, 30: 263–275.
29. Wisniewski T, Goni F. Immunotherapeutic approaches for Alzheimer’s disease. Neuron 2015, 85: 1162–1176.
30. Orsini F, DeBlasio D, Zangari R, Zanier ER, DeSimoni MG. Versatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis. Front Cell Neurosci 2014, 8: 380.
31. Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol 1982, 57: 239–242.
32. Veerhuis R, Nielsen HM, Tenner AJ. Complement in the brain. Mol Immunol 2011, 48: 1592–1603.
33. Nilsson P, Saido TC. Dual roles for autophagy: degradation and secretion of Alzheimer’s disease Abeta peptide. Bioessays 2014, 36: 570–578.
34. Tramutola A, Triplett JC, DiDomenico F, Niedowicz DM, Murphy MP, Coccia R, et al. Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD. J Neurochem 2015, 133: 739–749.
35. Pujhari S, Kryworuchko M, Zakhartchouk AN. Role of phosphatidylinositol-3-kinase (PI3K) and the mammalian target of rapamycin (mTOR) signalling pathways in porcine reproductive and respiratory syndrome virus (PRRSV) replication. Virus Res 2014, 194: 138–144.
36. Jack CR, Jr., Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, et al. An operational approach to National Institute on Aging-Alzheimer’s Association criteria for preclinical Alzheimer disease. Ann Neurol 2012, 71: 765–775.
37. Hefti F, Goure WF, Jerecic J, Iverson KS, Walicke PA, Krafft GA. The case for soluble Abeta oligomers as a drug target in Alzheimer’s disease. Trends Pharmacol Sci 2013, 34: 261–266.
38. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 2010, 6: 108–119.
39. Zhang J, Wu X, Qin C, Qi J, Ma S, Zhang H, et al. A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and beta-amyloid plaques in a mouse model of Alzheimer’s disease. Neurobiol Dis 2003, 14: 365–379.
40. Panza F, Solfrizzi V, Imbimbo BP, Tortelli R, Santamato A, Logroscino G. Amyloid-based immunotherapy for Alzheimer’s disease in the time of prevention trials: the way forward. Expert Rev Clin Immunol 2014, 10: 405–419.
41. Lambracht-Washington D, Qu BX, Fu M, Eagar TN, Stuve O, Rosenberg RN. DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model. JAMA 2009, 302: 1796–1802.
42. Faria AM, Weiner HL. Oral to lerance: mechanisms and therapeutic applications. Adv Immunol 1999, 73: 153–264.
43. Pride M, Seubert P, Grundman M, Hagen M, Eldridge J, Black RS. Progress in the active immunotherapeutic approach to Alzheimer’s disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener Dis 2008, 5: 194–196.
44. Wagner E, Frank MM. Therapeuti c potential of complement modulation. Nat Rev Drug Discov 2010, 9: 43–56.
45. Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, et al. The classical complement cascade mediates CNS synapse elimination. Cell 2007, 131: 1164–1178.
46. Aiyaz M, Lupton MK, Proitsi P, Powell JF, Lovestone S. Complement activation as a biomarker for Alzheimer’s disease. Immunobiology 2012, 217: 204–215.
47. Benoit ME, Hernandez MX, Dinh ML, Benavente F, Vasquez O, Tenner AJ. C1q-induced LRP1B and GPR6 proteins expressed early in Alzheimer disease mouse models, are essential for the C1q-mediated protection against amyloidbeta neurotoxicity. J Biol Chem 2013, 288: 654–665.
48. Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci 2008, 28: 6333–6341.
49. Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, Quigg RJ, et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer’s mice. Proc Natl Acad Sci U S A 2002, 99: 10837–10842.
50. Liu YH, Giunta B, Zhou HD, Tan J, Wang YJ. Immunotherapy for Alzheimer disease: the challenge of adverse effects. Nat Rev Neurol 2012, 8: 465–469.
51. Condello C, Yuan P, Schain A, Grutzen dler J. Microglia constitute a barrier that prevents neurotoxic protofibrillar Abeta42 hotspots around plaques. Nat Commun 2015, 6: 6176.
52. Zhang Y, Zou J, Yang J, Yao Z. 4Abeta 1-15-derived monoclonal antibody reduces more abeta burdens and neuroinflammation than homologous vaccine in APP/PS1 Mice. Curr Alzheimer Res 2015, 12: 384–397.
53. Guan X, Yang J, Gu H, Zou J, Yao Z. Im munotherapeutic efficiency of a tetravalent Abeta1-15 vaccine in APP/PS1 transgenic mice as mouse model for Alzheimer’s disease. Hum Vaccin Immunother 2013, 9: 1643–1653.
54. Lee CY, Landreth GE. The role of microg lia in amyloid clearance from the AD brain. J Neural Transm 2010, 117: 949–960.
55. Prokop S, Miller KR, Heppner FL. Microgl ia actions in Alzheimer’s disease. Acta Neuropathol 2013, 126: 461–477.
56. McGeer PL, Mc Geer EG. The amyloid cascade -inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol 2013, 126: 479–497.
57. Lionaki E, Markaki M, Tavernarakis N. Auto phagy and ageing: insights from invertebrate model organisms. Ageing Res Rev 2013, 12: 413–428.
58. Martinez-Vicente M, Cuervo AM. Autophagy an d neurodegeneration: when the cleaning crew goes on strike. Lancet Neurol 2007, 6: 352–361.
59. Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A, et al. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol 2005, 64: 113–122.
60. Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, et al. Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer’s disease. J Neurosci 2008, 28: 6926–6937.
61. Caccamo A, DePinto V, Messina A, Branca C, Od do S. Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer’s disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature. J Neurosci 2014, 34: 7988–7998.
62. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012, 8: 445–544.
63. Perluigi M, DiDomenico F, Butterfield DA. mTOR signaling in aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of autophagy. Neurobiol Dis 2015.
64. Heras-Sandoval D, Perez-Rojas JM, Hernandez-Damian J, Pedraza-Chaverri J. The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration. Cell Signal 2014, 26: 2694–2701.
65. Zhu Z, Yan J, Jiang W, Yao XG, Chen J, Chen L, et al. Arctigenin effectively ameliorates memory impairment in Alzheimer’s disease model mice targeting both beta-amyloid production and clearance. J Neurosci 2013, 33: 13138–13149.
66. Valdor R, Macian F. Autophagy and the regulation o f the immune response. Pharmacol Res 2012, 66: 475–483.
67. Chen M, Hong MJ, Sun H, Wang L, Shi X, Gilbert BE, et al. Essential role for autophagy in the maintenance of immunological memory against influenza infection. Nat Med 2014, 20: 503–510.
68. Puleston DJ, Zhang H, Powell TJ, Lipina E, Sims S, P anse I, et al. Autophagy is a critical regulator of memory CD8(+) T cell formation. Elife 2014, 3.
69. Lin LT, Dawson PW, Richardson CD. Viral interactions with macroautophagy: a double-edged sword. Virology 2010, 402: 1–10.
70. Jack CR, Jr., Knopman DS, Jagust WJ, Shaw LM, Aisen P S, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol 2010, 9: 119–128.
71. Jack CR, Jr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013, 12: 207–216.
72. Bloom GS. Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 2014, 71: 505–508.
73. Lemere CA. Developing novel immunogens for a safe and ef fective Alzheimer’s disease vaccine. Prog Brain Res 2009, 175: 83–93.
74. Sperling R, Mormino E, Johnson K. The evolution of precli nical Alzheimer’s disease: implications for prevention trials. Neuron 2014, 84: 608–622.
75. Yang C, Xiao S. New developments of clinical trial in immu notherapy for Alzheimer’s disease. Curr Pharm Biotechnol 2015, 16: 484–491.
76. Herzog C. Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature. Expert Rev Vaccines 2014, 13: 399–415.